Brazil's ANVISA lowers barriers for some product registrations

22 August 2016
drugs_pills_tablets_big

The National Agency for Health Vigilance (ANVISA), the medicines regulator in Brazil, has increased the list of health products which, because of lower risk, are subject to less rigorous rules to obtain the renewal of country registration.

The new arrangement includes 37 products in the simplified notification list, amongst which are folic acid, salts for oral hydration or rehydration and ferrous sulphate.

The president of ANVIS, Jarbas Barbosa, affirmed that the measure, apart from facilitating the introduction of new products to the market permits the Agency professionals to concentrate their efforts on the analysis of products considered to have a higher risk. “It is a step which will bring more agility in evaluation,” he said. With the new version, the number of products with simpler rules for obtaining ANVISA registration grows by 112. The list will be reviewed periodically. The last update was in 2009.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics